Target Delineation. For Head and Neck Cancer

Similar documents
Head and Neck Treatment Planning: A Comparative Review of Static Field IMRT Rapid Arc Tomotherapy HD

Multidisciplinary Management of Head and Neck Cancer I

Concurrent Chemotherapy and Radiotherapy for Head and Neck Cancer

IV. DEFINITION OF LYMPH NODE GROUPS (FIGURE 1) Level IA: Submental Group

Soft Tissue Neck CT Anatomy

Proton Therapy for Prostate Cancer

TNM Staging of Head and Neck Cancer and Neck Dissection Classification

Elective Clinical Target Volumes in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas

Particle Therapy for Lung Cancer. Bradford Hoppe MD, MPH Assistant Professor University of Florida

Evolution of Head and Neck Treatment Using Protons. Mayank Amin, M.Sc,CMD

Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.

Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda

IMRT for Prostate Cancer. Robert A. Price Jr., Ph.D. Philadelphia, PA

Oropharyngeal carcinoma State of the Art

Objectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background

THE DOSIMETRIC EFFECTS OF

TNM STAGING OF HEAD AND NECK CANCER AND NECK DISSECTION CLASSIFICATION

Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms

Guidelines for the treatment of breast cancer with radiotherapy

Target Volumes for Anal Carcinoma For RTOG 0529

Current and Future Trends in Proton Treatment of Prostate Cancer

Prostate IMRT: Promises and Problems Chandra Burman, Ph.D. Memorial Sloan-Kettering Cancer Center, New York, NY 10021

Extramedullary Plasmacytoma

TNM Staging of Head and Neck Cancer and Neck Dissection Classification

Treatment Volume and Technique

Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.

Proton Therapy for Head & Neck Cancers

Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation

Recurrent & Persistent Papillary Thyroid Cancer Central Nodal Dissection vs. Node-Picking Patterns of Nodal Metastases Recurrent Laryngeal Nerve,

Radiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015

Intensity Modulated Radiation Therapy (IMRT) for Thyroid Cancer

Acknowledgement. Prerequisites: Basic Concepts of IMRT. Overview. Therapy Continuing Education Course Clinical Implementation of IMRT for Lung Cancers

IMRT For Head And Neck Cancer

Pediatric Oncology for Otolaryngologists

Automated Treatment Planning Using a Database of Prior Patient Treatment Plans

Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto

Management of low grade glioma s: update on recent trials

Approccio multidisciplinare nei tumori del retto

Corporate Medical Policy

Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology

RT for High-Risk and Postoperative

The Axial Skeleton Eighty bones segregated into three regions

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER

Treating Thyroid Cancer using I-131 Maximum Tolerable Dose Method

Calculation of Contra-lateral Lung Doses in Thoracic IMRT: An Experimental Evaluation

IBA Proton Therapy. Biomed days Vincent Bossier. System Architect Protect, Enhance and Save Lives

Daily IGRT with CT-on-Rails Can Safely Reduce Planning Margin for Prostate Cancer: Implication for SBRT

Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical

Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure

Case Number: RT (M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor

M D Anderson Cancer Center Orlando TomoTherapy s Implementation of Image-guided Adaptive Radiation Therapy

Implementation Date: April 2015 Clinical Operations

Small Cell Lung Cancer

Current Status and Perspectives of Radiation Therapy for Breast Cancer

IGRT. IGRT can increase the accuracy by locating the target volume before and during the treatment.

intensity_modulated_radiation_therapy_imrt_of_abdomen_and_pelvis 11/2009 5/2016 5/2017 5/2016

Radiation Protection in Radiotherapy

Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy

Rectal Cancer. To Radiate or not to radiate? Q: Should rectal cancer RT/CRT decisions be based solely on stage? 11/09/2014

ATLAS FOR THE DELINEATION OF THE POSTOPERATIVE TREATMENT OF PANCREATIC CANCER

National Clinical Trials Network Groups Update Fall 2014

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Breast Cancer Accelerated Partial Breast Irradiation Bruce G. Haffty, MD Professor and Chairman Dept Radiation Oncology UMDNJ-RWJMS Cancer Institute

Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology

CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA

RADIATION THERAPY FOR BLADDER CANCER. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

Carcinoma rettale: ruolo della radioterapia

9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH

The Science behind Proton Beam Therapy

Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla

Innovative RT SBRT. The variables with REQ in superscript are required.

Lung Cancer Treatment Guidelines

Pancreatic Cancer: FDA Approved Treatments and Clinical Trials

Proton Therapy: Cutting Edge Treatment for Cancerous Tumors. By: Cherilyn G. Murer, JD, CRA

Dosimetric impact of the 160 MLC on head and neck IMRT treatments

Chapter 7: Clinical Treatment Planning in External Photon Beam Radiotherapy

GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision

Failure Modes and Effects Analysis (FMEA)

Department of Radiation Oncology

RT for High-Risk and Post- operative Prostate Cancer ASTRO Refresher Course 2014

ASTRO Spring Refresher Course 2013: Early Breast Cancer

Current Status and Future Direction of Proton Beam Therapy

TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.

Management of Non-Small Cell Lung Cancer Guide for General Practitioners

Clinical Education A comprehensive and specific training program. carry out effective treatments from day one

Manual VIRTUAL RADIATION ONCOLOGY CLINIC (VROC) (1.1) Radiation Oncology Training. Director User Manual (1.1)

Management of spinal cord compression

Veterinary Oncology: The Lumps We Hate To Treat

Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE

Transcription:

Target Delineation For Head and Neck Cancer Nasopharyngeal and Oropharyngeal CA Nancy Lee, M.D. Department of Radiation Oncology Memorial Sloan-Kettering Cancer Center

Delineation of the Gross Target Volume or GTV

Two Issues Issue of Using IV contrast? Contrast Density:? Dose Calculation Amount of contrast needs adjustment? At MSKCC, routine use of IV contrast at simulation How about Image Fusion? MRI: Head & Neck don t match PET: What is the right window level?

CT vs. MRI vs. PET volume Final GTV Thiagarajan A. et al. ASTRO 2010 PET MRI Importance of Physical Examination

Added Value of MRI: Particularly for the skull base

All NPC patients Need MRI unless Medically Contrainicated T1 weighted Image Without Contrast T1 disease changed to T3 disease

Current MSKCC Dose Painting Guidelines Gross Disease PTV 70 : 70 Gy over 33 Days (2.12 Gy) High Risk Subclinical PTV 59.4 : 59.4 Gy over 33 Days (1.8 Gy) Lower Risk Subclinical PTV 54 54 Gy over 33 Days(1.64 Gy)

GTV 70 to PTV 70 GTV: Gross tumor based on imaging, PE GTV is also known as CTV 70 PTV 70 : GTV + 3-5mm (based on you comfort level)

Primary and nodal GTV 70 PTV 70 : GTV 70 + 3mm Margin T2N2C BOT

IMRT Head and Neck Cancer CTV Delineation Knowledge of Patterns of Spread RTOG, EORTC, DAHANCA N0 and non-surgically violated neck nodal atlas: www.rtog.org No Other Consensus

Nasopharynx(Primary): CTV 59.4 Delineation Sphenoid Sinus Cavernous Sinus Skull base Clivus posterior 1/3 maxillary sinus(pterygopalatne fossae where 2 resides) Posterior 1/3 of nasal cavity parapharyngeal space(where 3 resides) retropharyngeal space Inferiorly Soft Palate

Anterior Coverage Post 1/3 of Max Sinus Nasal Cavity CTV 59.4 RLN Pterygoid Fossae Parapharyngeal Fat GTV Retropharyngeal Lymph Nodal Region T2 Skull Base Clivus Sphenoid Sinus

Coverage of Sphenoid Sinus, Cavernous Sinus CTV 59.4 PTV 59.4 PTV 70 CTV 59.4 + 3mm = PTV 59.4

PTV 70 PTV 70 Coverage of Skull base Pterygopalatine Fossae

Coverage of Parapharyngeal Fat PTV 70

Nasopharynx(Nodal): CTV 59.4 Delineation Retrostyloid space Bilateral levels Ib through V Level Ib can be omitted in node negative disease

Coverage of Retrostyloid Space Regardless of N stage for NPC Retrostyloid Spaces

Coverage of level V

Level V Nodal Coverage High Risk PTV Low Risk PTV

If choosing to use beam Split technique, Make sure use AP/PA with midline block For all NPC cases as nodes can spread posteriorly

Oropharynx (Primary) CTV 59.4 Delineation Should probably have at least 1cm circumferential margin except near bony region, especially there are no good salvage options for failure Base of tongue cancer to include pre-epiglottic fat and entire base of tongue (but can be in the next lower dose region) Tonsil cancer, should include the pterygoid plate (ensuring good coverage superiorly of pterygoid mandibular raphe).

Ensuring Coverage of Pre-epiglottic space

Need to Include Pterygoid Plate Look at the growth pattern of your cases to determine CTV 59.4 coverage

Oropharynx (Nodal): CTV 59.4 Delineation Node+: levels IB-V Can consider shrinking volume, just treat levels Ib-IV or II- IV in node positive cases Node negative: levels II-IV At MSKCC, we no longer perform routine planned neck dissection. IMRT with precise targeting of the gross neck nodes has changed practice

CTV low neck For oropharynx CA Not treating level V CTV 54 CTV 59.4

Base of Tongue CA PTV 70 CTV 59.4 PTV 59.4 PTV 59.4

Example Stage IVB oropharynx CA Superior to Inferior slices Treat Bilateral Retrostyloid Spaces

Distance from GTV To PTV59.4 is at least 1.3 cm No actively trying to spare Constrictor muscles

Coverage of pre-epiglottic fat but spare larynx Even with N+, level V not included

Node-: CTV 54 Delineation Levels II-IV Coverage of the retropharyngeal region. For oropharyngeal CA, when posterior belly of digastric just crosses IJ, can omit treating high level II, i.e, only target subdigastric nodes. (Omitting the retrostyloid space) CTV 54 + 3mm = PTV 54

Omit high levels IIA/IIB N- Neck Typically around C2

PTV 54 Gy PTV 59.4 Gy PTV 54 Gy PTV 59.4 Gy PTV 70 Gy N- Contralateral Neck Can Spare the high IIA/IIB nodes

PTV 70 PTV 59.4 PTV 54 Coverage of Retropharyngel Region Bilaterally But omitting contralateral Retrostyloid space

Retropharyngeal Space N+ N-

Contour at RP nodal level for bilateral N+ neck Univ Michigan MSKCC

Superior Aspect of Nodal CTV for Contralateral N0 Neck MSKCC U Michigan MDACC C1 Courtesy of Q Le, ASTRO Practicum 2008

Can We further Dose Paint? Even a lower risk microscopic region!

Perhaps we should have CTV 50 PTV 59.4 PTV 50 PTV 70 PTV 54 Apisarnthanarax S, IJROBP 64(3);678-83, 2006

PTV 50 BED calculation is 57.6 for tumoricial effect. BED for 44 Gy at 2 Gy per fraction: 52.8 BED for 50 Gy at 2 Gy per fraction: 60

Chemotherapy: 85% IMRT for NPC: UCSF (UCSF, Lee et al, IJROBP, 53:1:12-21) N = 87 PTVg = 70 Gy @ 2.12 Gy concurrently PTVm = 59.4 Gy @ 1.8 Gy per day T3/T4: 45% III/IV: 74% N+: 79%

% Local PF Rate 4 Year Local Progression-free 100 90 80 70 60 50 40 30 20 10 97% N=87 Median F/U=30 months 0 0 10 20 30 40 Months 50 60 70 80

RTOG PROTOCOL 0225 IMRT for NPC (Lee N., JCO 2009) Stage: I-IVb Histology: WHO I-III R E G I S T E R 70 Gy to gross disease concurrently 59.4 Gy to microscopic disease Over 33 days CT:( T2b and/or + LN

Local Progression-Free Interval 3 year: 92.6% (34% T3/4) 1 local failure only 3 local regional failures Lee et al, JCO, 2009

Regional Progression-Free Interval 3 year 90.8% (43% N2/3) 2 regional failures only 5 local and regional failures Lee et al, JCO, 2009

IMRT for Oropharynx: Patients Population From 9/1998 to 4/2009 442 patient treated with IMRT for OPC (SCC, M0) Site : Stage: Tonsil 50% Base of Tongue 46% Soft Palate 2% Pharyngeal wall 2% T2 42%, T3 18%, T4 14% N1 21%, N2 67%, N3 3% Stage III 19%, Stage IV 76% (91% received chemotherapy Setton et al. IJROBP Submitted

Oropharyngeal Ca: IMRT (n=445) Local Control 3-year 94.4% 5-year 94.4% Median FU 36.8 months

Regional Control 3-year 94.3% 5-year 94.3%

OS, DMFS and Statistics OS : 3 years 84.9% 5 years 78.7% DMFS : 3 years 87.1% 5 years 85.2% Univariate (Logrank) Multivariate (Cox) T1/2 vs T3/4 N0/1 vs N2/3 T1/2 vs T3/4 N0/1 vs N2/3 OS p < 0.0001 p = 0.005 p < 0.0001 p = 0.009 LC p = 0.05 NS RC NS NS DM p = 0.01 p = 0.001 p = 0.01 p = 0.02 NS: Site, Age, Treatment Modality, Histology

IMRT for oropharynx: available data

Conclusion As we enter the era of such high precision radiotherapy treatment for our patients, it is CRUCIAL that our targets and normal tissues are drawn accurately. Remember that the best chance for cure is the first chance. Study each failure carefully!